Doctor’s Guide -- GOTHENBURG, Sweden -- October 17, 2010 -- Patients with multiple sclerosis (MS) who are switched from standard therapy with intramuscular interferon (IFN) beta-1a to oral fingolimod achieve significant reductions in relapse rate and other signs of disease activity, researchers announced at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
